Zopolrestat

TargetMol
Product Code: TAR-T35317
Supplier: TargetMol
CodeSizePrice
TAR-T35317-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-2mg2mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-5mg5mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-1mL1 mL * 10 mM (in DMSO)£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-10mg10mg£145.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-25mg25mg£242.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T35317-50mg50mg£348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Zopolrestat is a potent inhibitor of aldose reductase (IC50 = 3.1 nM).
CAS:
110703-94-1
Formula:
C19H12F3N3O3S
Molecular Weight:
419.38
Pathway:
Metabolism; Endocrinology/Hormones
Purity:
0.98
SMILES:
OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2ccccc12
Target:
Reductase

References

Zhai J, et al. Zopolrestat as a human glyoxalase I inhibitor and its structural basis. ChemMedChem. 2013 Sep;8(9):1462-4. Badawy D, et al. Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity. Can J Physiol Pharmacol. 2013 Feb;91(2):101-7. Ramasamy R, et al. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor zopolrestat. Cardiovasc Res. 1999 Apr;42(1):130-9. Mylari BL, et al. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J Med Chem. 1991;34(1):108-122.